This will be the first time the GALEAS™ Bladder test will be available to UK patients. It offers an alternative to the traditional method of diagnosing bladder cancer through cystoscopy. Instead of undergoing the uncomfortable hospital procedure, individuals suspected of having bladder cancer can provide a urine sample from home. The test detects genetic markers in the sample, which is then sent to Informed Genomics’ accredited lab for analysis.
According to Bupa, the test can detect genetic mutations associated with 96 % of bladder cancers at all stages and grades – equivalent results to cystoscopy.
Dr Tim Woodman, medical director for cancer services at Bupa Insurance said: ‘We’re pleased to be partnering with Informed Genomics to be the first UK health insurer to cover the GALEAS Bladder test for our customers. It provides a more efficient solution to diagnosing bladder cancer, where getting that diagnosis a few days or weeks earlier could make a crucial difference.’
Clinical laboratory director at Informed Genomics Lauren Silcock said the technology could spare thousands of patients the discomfort of receiving a flexible cystoscopy, while freeing up clinicians’ time and resources to deal with the most urgent patients.
‘Our collaboration with Bupa is an important first step in making the GALEAS Bladder test available to patients in the UK and around the world. We’re working hard to make the test available more widely, through other healthcare providers and the NHS,’ she said.